cardiac & neurological research

from Bock-Marquette's Nature 2004 cardiac repair study to neurological protection and progenitor cell activation

Heart and Brain

Bock-Marquette (Nature, 2004) showed TB4 activated cardiac progenitor cells and improved heart function after MI in mice. That landmark seeded RegeneRx.

Parallel animal work flags neuroprotective signals in TBI, stroke, and MS models. This unit walks why pharma money never produced an approved drug.

~50%

infarct-size reduction in mice (Bock-Marquette 2004)

2001

RegeneRx licenses TB4

Phase 2

where the cardiac program stalled

RGN-259

only surviving clinical path (ophthalmic)

Map the Organ Findings

Click a system to pull its animal studies.

organ research map

Nature 2004: the study that seeded RegeneRx

TB4-treated mice vs saline controls across the four post-MI metrics Bock-Marquette measured -- and why dose timing mattered nearly as much as dose.

tb4 vs control -- post-MI cardiac metrics

Knowledge Check

Test what you've learned in this unit.

Practice Exercises

Reinforce your understanding.